Tompkins Financial Corp Has $1.57 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Tompkins Financial Corp increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 44.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,795 shares of the biopharmaceutical company's stock after buying an additional 19,059 shares during the quarter. Tompkins Financial Corp's holdings in Pfizer were worth $1,566,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at $26,000. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC lifted its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.0%

Shares of PFE traded up $0.01 on Friday, reaching $23.46. 56,576,195 shares of the company's stock were exchanged, compared to its average volume of 41,238,850. The business has a 50 day moving average price of $23.12 and a two-hundred day moving average price of $25.07. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market capitalization of $133.38 billion, a P/E ratio of 16.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.82 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.33%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PFE shares. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.